Analysis Affinity of LSN2478185 and LY2495655 with Myostatin by KinExA (CAT#: STEM-MB-0027-CJ)

Introduction

Cancer cachexia is a multifactorial syndrome defined as persistent loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed with regular nutritional support and leads to progressive sexual dysfunction. Myostatin has been identified as a negative regulator of skeletal muscle mass from the muscular hyperplasia phenotypes of naturally occurring subtypes and knockout mice. Reduction or overexpression of myostatin can lead to skeletal muscle hypertrophy and atrophy, respectively. Increased myostatin levels and pathway activation were found in preclinical models of cancer cachexia as well as in atrophic muscles of cancer patients. LSN2478185 is a myostatin neutralizing murine IgG1 monoclonal antibody and its derivative LY2495655, which is humanized and neutralizing monoclonal antibody against myostatin and significantly alleviates loss of skeletal muscle mass and function associated with tumor load.